International CDKL5 Clinical Research Network

Description

Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.

Conditions

CDKL5, CDKL5 Deficiency Disorder, CDD

Study Overview

Study Details

Study overview

Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.

Multi-Site Validation of Biomarkers and Core Clinical Outcome Measures for Clinical Trials Readiness in CDKL5 Deficiency Disorder

International CDKL5 Clinical Research Network

Condition
CDKL5
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California Los Angeles/UCLA Mattel Children's Hospital, Los Angeles, California, United States, 90095

Aurora

University of Colorado Denver/Children's Hospital Colorado, Aurora, Colorado, United States, 80045

Boston

Harvard Medical School/Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Saint Louis

Washington University in St. Louis/St. Louis Children's Hospital, Saint Louis, Missouri, United States, 63110

New York

NYU Langone Health, New York, New York, United States, 10016

Cleveland

Cleveland Clinic Foundation, Cleveland, Ohio, United States, 44195

Philadelphia

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104

Houston

Baylor College of Medicine/ Texas Children's Hospital, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All children diagnosed with CDD age 1-month to 100 years of age that are receiving care at one of the study institutions or are registered with the International CDKL5 Disorder Database will be considered for the study population.
  • * Individuals who do not meet study inclusion criteria.

Ages Eligible for Study

1 Month to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Timothy A Benke, MD PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2027-02-15